Production advantage

Since its establishment, the company has focused on research in the field of biotechnology and R&D of bio-high-tech products. As of December 2023, the company has 230 patented technologies, including 171 domestic patents (9 invention patents) and 59 overseas patents (7 Invention patents). Obtained 45 NMPA certificates, EU CE certificates covering 603 products, and 3 US FDA 510(k) certificates covering 21 test products. Products are sold to more than 100 countries and regions around the world.

Professional team

Biotest is one of the manufacturers with a relatively complete variety of POCT diagnostic reagents in the world. Relying on strong independent innovation and management capabilities, Biotest has established a rapid immunodiagnosis platform, a POCT application technology platform, a biological core raw material technology platform, an automated production technology platform and other industrial technology platforms.

After -sales

Biotest products are currently sold in over 100 countries and regions worldwide, serving a population of over 3 billion. We have partners all over the world. We are expanding our distribution network in Asia, Africa, America and Europe. We are looking forward to more and better global partners to join us, and together we can provide the world with more timely, more accurate and more affordable diagnostic solutions.